Taro Pharmaceutical, a subsidiary of Sun Pharmaceutical, has initiated a recall of over 17,000 units of an antifungal shampoo ...

Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & loss statements.

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and ...

Sun Pharma Dividend 2025: Sun Pharma, the pharma company, is set to trade ex-date and record date on February 6, 2025. The state-run company announced a 1,050 per cent dividend payment on each stock ...

We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,' the drug maker said.

PRINCETON, N.J., Oct. 22, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma ...

Taro Pharmaceutical Industries, a unit of Sun Pharma, is recalling over 17,000 units of an antifungal medication in the US ...

Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth ...

Sun Pharma’s focus areas involve investing in research and development (R&D) to further build its pipeline of innovative medicines.

Sun Pharma highlights obesity treatment drugs as a growth driver for India's pharma industry, enhancing access to GLP-1 ...

Sun Pharma-owned Taro Pharmaceutical is recalling over 17,000 units of antifungal Ciclopirox Shampoo in the US due to ...